Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is listed today as Aurinia Pharmaceuticals Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2014 | $52 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Aurinia Pharmaceuticals Inc., its revenue in fiscal 2025 came from these product and service lines: License, collaboration and royalty revenue $11.71 million (4%).
Annual report (SEC XBRL) · Dec 2025
Aurinia Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2014).
SEC Form D · Feb 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2014
Products and services#
No products or services of Aurinia Pharmaceuticals Inc. are on record.
Investors#
No investor of Aurinia Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.
Largest shareholders today
Institutions holding Aurinia Pharmaceuticals Inc. shares, as of Sep 30, 2026.
- Tang Capital Management LLC$211 M9.73%
- BlackRock, Inc.$139 M6.41%
- Goldman Sachs Group Inc$103 M4.73%
- NEA Management Company, LLC$64 M2.96%
- Arrowstreet Capital, Limited Partnership$48 M2.23%
- Two Sigma Investments, LP$48 M2.20%
- State Street Corp$42 M1.93%
- Marshall Wace, LLP$31 M1.42%
- LSV Asset Management$29 M1.35%
- Morgan Stanley$29 M1.34%
- Geode Capital Management, LLC$28 M1.28%
- Renaissance Technologies LLC$23 M1.07%
- Vanguard Portfolio Management LLC$21 M0.96%
- Nuveen, LLC$20 M0.93%
- Jacobs Levy Equity Management, Inc$20 M0.91%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dennis M. Bourgeault | Executive officer | Feb 2014 |
| Michael M. Martin | Executive officer | Feb 2014 |
| Richard M. Glickman | Executive officer | Feb 2014 |
| Stephen W. Zaruby | Executive officer | Feb 2014 |
| Benjamin M. Rovinski | Director | Feb 2014 |
| Chris M. Kim | Director | Feb 2014 |
| Daniel M. Park | Director | Feb 2014 |
| Donald M. Wyatt | Director | Feb 2014 |
| Kurt von M. Emster | Director | Feb 2014 |
| Michael M. Martin | Director | Feb 2014 |
| Peter M. Wijngaard | Director | Feb 2014 |
| Richard M. Glickman | Director | Feb 2014 |
| Stephen W. Zaruby | Director | Feb 2014 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.